MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$19,591,231
EPS
-$0.11
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
13,393,464
10,839,150
10,412,150*
7,649,697
Selling, general and administrative
7,657,531
7,376,123
6,258,228*
5,611,503
Change in fair value
0
373,354
97,071.5*
492,827
Total costs and expenses
21,050,995
17,841,919
16,573,306.5
12,768,373
Loss from operations
-21,050,995
-17,841,919
-16,573,306.5*
-12,768,373
Other income
1,459,764
1,461,079
1,082,822*
838,093
Net loss
-19,591,231
-16,380,840
-15,490,484.5
-11,930,280
Basic EPS
-0.11
-0.1
-0.135
-0.13
Diluted EPS
-0.11
-0.1
-0.135
-0.13
Basic Average Shares
174,571,543
172,306,932
114,869,972
90,050,973
Diluted Average Shares
174,571,543
172,306,932
114,869,972
90,050,973
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$19,591,231
(-97.58%↓ Y/Y)
Other income
$1,459,764
(59.23%↑ Y/Y)
Loss from operations
-$21,050,995
(-94.34%↓ Y/Y)
Total costs and
expenses
$21,050,995
(94.34%↑ Y/Y)
Research and development
$13,393,464
(154.10%↑ Y/Y)
Selling, general and
administrative
$7,657,531
(29.36%↑ Y/Y)
Buy us a coffee
Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc. (IKT)